1. Home
  2. RNTX vs SFWL Comparison

RNTX vs SFWL Comparison

Compare RNTX & SFWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.71

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Logo Shengfeng Development Limited

SFWL

Shengfeng Development Limited

HOLD

Current Price

$0.95

Market Cap

72.7M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNTX
SFWL
Founded
2001
2001
Country
United States
China
Employees
10
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trucking Freight/Courier Services
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
65.3M
72.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RNTX
SFWL
Price
$0.71
$0.95
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
396.6K
13.0K
Earning Date
05-15-2026
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$6.06
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.56
52 Week High
$2.18
$1.29

Technical Indicators

Market Signals
Indicator
RNTX
SFWL
Relative Strength Index (RSI) 31.69 53.74
Support Level N/A $0.84
Resistance Level $1.32 $1.03
Average True Range (ATR) 0.08 0.09
MACD -0.01 0.02
Stochastic Oscillator 6.72 58.91

Price Performance

Historical Comparison
RNTX
SFWL

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About SFWL Shengfeng Development Limited

Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The company's operations are based in the PRC. Its integrated logistics solutions are comprised of three business streams: B2B freight transportation services; cloud storage services; and value-added services. The company derives maximum revenue from Transportation, followed by Warehouse storage management services. The solutions provides by the company are : Internet TV; Electronic communication; Textiles and Apparel; Automotive parts; and e-commerce.

Share on Social Networks: